[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569885":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Institut Bergonié","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Nadège ANIZAN","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+33556333347","n.anizan@bordeaux.unicancer.fr",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Institut Bergonie","RECRUITING","Bordeaux","33600","France","FR",{"type":26,"coordinates":27},"Point",[28,29],-0.58046,44.84124,{"lat":29,"lon":28},[32,33],{"name":10,"role":14,"phone":7,"phoneExt":7,"email":16},{"name":34,"role":14,"phone":7,"phoneExt":7,"email":35},"Caroline LALET","c.lalet@bordeaux.unicancer.fr",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100569885","clinical-and-dosimetric-study-of-patients-treated-with-177lu-psma-617-for-prostate-cancer-100569885",false,"NCT06700057","Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.","Optimisation and Safety of an Innovative Nuclear Medicine Treatment: Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.","DOSIPROSTATE","Inclusion Criteria:\n\n1. Patient aged 18 and over.\n2. Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01\u002F11\u002F2023:\n\n   1. Progressive, metastatic, castration-resistant prostate cancer,\n   2. overexpressing prostate specific membrane antigen (PSMA)\n   3. treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone).\n3. Patient able to lie still for 1 hour for image acquisition.\n4. Patient's place of residence \\\u003C 2 hours' drive from the Institut Bergonié.\n5. Patient has not expressed any opposition to the use of his\u002Fher medical data for research purposes.\n\nExclusion Criteria:\n\nNone","MALE","18 Years",{"count":49,"type":50},50,"ESTIMATED","OBSERVATIONAL","Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.",[54,55],"Prostate Cancer","Metastasis",[57],"Radiopharmaceutical drug","2026-01-28",{"date":60,"type":61},"2026-01-30","ACTUAL",{"date":63,"type":61},"2023-11-01",{"date":65,"type":50},"2027-12-31",{"name":5,"class":6},1]